ArticleHeadache2026
Visual, vestibular, and ocular motor changes during nitroglycerin-triggered vestibular migraine.
Article in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIntravenous nitroglycerin (NTG) is a well-established model for provoking migraine attacks, but it has not previously been used to characterize vestibular migraine (VM). Different types of nystagmus have been reported during spontaneous VM attacks. We aimed to measure changes in nystagmus during NTG-induced migraine in participants with VM.
methodsWe studied 20 participants with definite VM (Barany-International Classification of Headache Disorders, 3rd edition criteria) undergoing NTG provocation in a prospective, within-subject repeated-measures pharmacological provocation study under three conditions at the National Institute for Health and Care Research King's Clinical Research Facility, London, between November 2024 to December 2025. Median (interquartile range [IQR]) age was 32 (29 to 38) years, and 16/20 were female. 3D video-oculography was used to quantify total slow-phase velocity (SPV) (°/s) of nystagmus without fixation in the center, left, right, up, and down positions. Recordings were repeated before NTG, after NTG, and after subcutaneous sumatriptan. Subjective vestibular symptoms and headache intensity were quantified with an ordinal numeric scale. Longitudinal changes in SPV were analyzed.
resultsAll the participants developed headache, with median peak severity 6/10 (IQR 4 to 7). Vestibular symptoms were triggered in 14/20 participants following NTG, with a median maximum intensity of 2.5 (IQR 0 to 4). Median (IQR) summed SPV (°/s) was 2 (1 to 3.25) at baseline, 1.5 (0 to 4.75) following NTG, and 1 (0 to 2.75) after sumatriptan. In Tweedie generalized linear mixed-effects models, no significant group-level effect of condition on total SPV was detected. Estimated marginal means were 1.87 (95% confidence interval [CI] 1.02 to 3.41) at baseline, 2.10 (95% CI 1.16 to 3.80) following NTG, and 1.73 (95% CI 0.93 to 3.19) after sumatriptan. Compared with baseline, neither NTG (β = 0.118, standard error [SE] = 0.267, P = 0.658) nor sumatriptan (β = -0.078, SE = 0.278, P = 0.780) showed significant effects. NTG provocation was associated with complex perceptions such as visual symptoms (10/20) and Alice in Wonderland syndrome type or dissociative symptoms (6/20), including derealization/depersonalization, metamorphopsia, macropsia and pelopsia, dysmorphopsia, and distorted passage of time.
conclusionsQuantitative slow phase velocity measures of nystagmus did not show a uniform group-level change during NTG provocation in VM, despite frequent subjective vestibular symptoms. VM episodes may reflect altered central sensory processing and vestibular hypersensitivity rather than changes in vestibulo-oculomotor output.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.